{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:06:07Z","timestamp":1761091567426,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vascn.2020.106899","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T21:34:01Z","timestamp":1595280841000},"page":"106899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Translation of in vitro cannabinoid 1 receptor agonist activity to in vivo pharmacodynamic endpoints"],"prefix":"10.1016","volume":"104","author":[{"given":"Stephen","family":"Jenkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.G.","family":"Goody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asser","family":"Bassyouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhys","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Otto-Bruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Duquennoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie K.","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Mead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2020.106899_bb0005","series-title":"IUPHAR\/BPS guide to pharmacology CITE, 2019","article-title":"Cannabinoid receptors (version 2019.4) in the IUPHAR\/BPS guide to pharmacology database","volume":"4","author":"Abood","year":"2019"},{"key":"10.1016\/j.vascn.2020.106899_bb0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jps.10332","article-title":"Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding","volume":"92","author":"Banker","year":"2003","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.vascn.2020.106899_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106609","article-title":"Safety screening in early drug discovery: An optimized assay panel","volume":"99","author":"Bendels","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2020.106899_bb0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2010.07.005","article-title":"Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists","volume":"59","author":"Bosier","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.vascn.2020.106899_bb0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: The use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2020.106899_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.60.1.155","article-title":"Evidence for a new G protein-coupled cannabinoid receptor in mouse brain","volume":"60","author":"Breivogel","year":"2001","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.vascn.2020.106899_bb0035","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.vascn.2020.106899_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pnpbp.2012.02.009","article-title":"Cannabinoid receptors: Nomenclature and pharmacological principles","volume":"38","author":"Console-Bram","year":"2012","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.vascn.2020.106899_bb0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(25)24023-X","article-title":"Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212","volume":"271","author":"Fan","year":"1994","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2020.106899_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/23328940.2015.1024383","article-title":"Induction of therapeutic hypothermia by pharmacological modulation of temperature-sensitive TRP channels: Theoretical framework and practical considerations","volume":"2","author":"Feketa","year":"2015","journal-title":"Temperature (Austin)"},{"key":"10.1016\/j.vascn.2020.106899_bb0055","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/nm.2235","article-title":"Nociceptor sensitization in pain pathogenesis","volume":"16","author":"Gold","year":"2010","journal-title":"Nature Medicine"},{"key":"10.1016\/j.vascn.2020.106899_bb0060","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/npp.2014.326","article-title":"The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus","volume":"40","author":"Kawai","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.vascn.2020.106899_bb0065","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0022-3565(25)13256-4","article-title":"Pharmacology and stereoselectivity of structurally novel cannabinoids in mice","volume":"247","author":"Little","year":"1988","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2020.106899_bb0070","first-page":"108","article-title":"Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids","volume":"79","author":"Martin","year":"1987","journal-title":"NIDA Research Monograph"},{"key":"10.1016\/j.vascn.2020.106899_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pbb.2013.04.011","article-title":"Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054","volume":"109","author":"McLaughlin","year":"2013","journal-title":"Pharmacology Biochemisty Behavior"},{"key":"10.1016\/j.vascn.2020.106899_bb0080","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1517\/17460441.2014.956077","article-title":"Appropriate experimental approaches for predicting abuse potential and addictive qualities in preclinical drug discovery","volume":"9","author":"Mead","year":"2014","journal-title":"Expert Opinion Drug Discovery"},{"key":"10.1016\/j.vascn.2020.106899_bb0085","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.drudis.2010.06.006","article-title":"Drug profiling: Knowing where it hits","volume":"15","author":"Merino","year":"2010","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.vascn.2020.106899_bb0090","doi-asserted-by":"crossref","first-page":"9.59.1","DOI":"10.1002\/cpns.31","volume":"80","author":"Metna-Laurent","year":"2017","journal-title":"Current Protocols in Neuroscience"},{"issue":"11","key":"10.1016\/j.vascn.2020.106899_bb0095","first-page":"487","article-title":"Cannabinoid ligands targeting TRP channels","author":"Muller","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.vascn.2020.106899_bb0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF02246955","article-title":"Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice","volume":"110","author":"Nevins","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.vascn.2020.106899_bb0105","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: Its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behavioral Neuroscience"},{"key":"10.1016\/j.vascn.2020.106899_bb0110","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vascn.2020.106899_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40429-014-0014-y","article-title":"Synthetic cannabinoids: Pharmacology, behavioral effects, and abuse potential","volume":"1","author":"Tai","year":"2014","journal-title":"Current Addiction Reports"},{"key":"10.1016\/j.vascn.2020.106899_bb0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.118.083279","article-title":"In vitro-in vivo extrapolation of key transporter activity at the blood-brain barrier","volume":"47","author":"Trapa","year":"2019","journal-title":"Drug Metabolism & Disposition"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920302288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920302288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:03:28Z","timestamp":1761005008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871920302288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":24,"alternative-id":["S1056871920302288"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106899","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of in vitro cannabinoid 1 receptor agonist activity to in vivo pharmacodynamic endpoints","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106899"}}